Seres Therapeutics (NASDAQ:MCRB) Rating Lowered to Sell at StockNews.com
Seres Therapeutics (NASDAQ:MCRB – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Tuesday. A number of other brokerages have also weighed in on MCRB. Chardan Capital reaffirmed a “buy” rating and issued a $1.25 price target on shares of Seres […]
Seres Therapeutics (NASDAQ:MCRB – Get Free Report) was downgraded by research analysts at StockNews.com from a “hold” rating to a “sell” rating in a report released on Tuesday. A number of other brokerages have also weighed in on MCRB. Chardan Capital reaffirmed a “buy” rating and issued a $1.25 price target on shares of Seres […]
